The life expectancy of patients with advanced gastric cancer depends on the pathological type of the tumor, the patient’s physical condition, treatment and other factors, and is usually about 1 year. Tegeo is a compound preparation that can be used for inoperable advanced gastric cancer as well as gastric cancer that has metastasized. Oral tegeo treatment for gastric cancer patients can inhibit the growth of tumor cells, improve the prognosis and enhance the quality of life of patients. If the tumor is highly malignant and has metastasized to multiple organs, the disease will deteriorate rapidly and cachexia will appear, and the patient’s life expectancy is only 3-6 months. If the tumor has low malignancy and is more sensitive to chemotherapeutic drugs, the patient’s life expectancy can be 1-2 years or even longer. Patients should standardize the medication under the guidance of doctors, taking it twice a day with meals and stopping it for 2 weeks after taking it for 4 weeks continuously. Side effects such as nausea, vomiting, loss of appetite, hematocrit, diarrhea, and interstitial pneumonia are promptly treated.